These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 730421)

  • 1. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. IV. Clinical implications of own observations with a recent review of literature.
    van der Vijgh WJ; Oe PL
    Int J Clin Pharmacol Biopharm; 1978 Nov; 16(11):540-6. PubMed ID: 730421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digitalis therapy in renal failure with special regard to digitoxin.
    Vöhringer HF; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):175-84. PubMed ID: 7021432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. II. On hemodialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):255-9. PubMed ID: 881277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Proceedings: Clinical value of serum digoxin and digitoxin determination in renal insufficiency].
    Klauser-Reucker C; Ferrini B; Klauser H; Moccetti T
    Schweiz Med Wochenschr; 1975 Dec; 105(51):1784-6. PubMed ID: 1215979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tritiated digoxin: studies in renal disease in human subjects.
    Doherty JE; Bissett JK; Kane JJ; de Soyza N; Murphy ML; Flanigan WJ; Dalrymple GV
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):89-95. PubMed ID: 1100542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic aspects of digoxin in patients with terminal renal failure III. Effect of heparin.
    van der Vijgh WJ; Oe PL
    Int J Clin Pharmacol Biopharm; 1977 Dec; 15(12):560-2. PubMed ID: 598950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digitalis pharmacokinetics and therapy with respect to impaired renal function.
    Kramer P
    Klin Wochenschr; 1977 Jan; 55(1):1-11. PubMed ID: 319291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of digoxin and digitoxin in patients undergoing hemodialysis.
    Finkelstein FO; Goffinet JA; Hendler ED; Lindenbaum J
    Am J Med; 1975 Apr; 58(4):525-31. PubMed ID: 1124790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Digoxon or digitoxin in patients with terminal kidney insufficiency in the dialysis stage?].
    Risler T; Peters U; Grabensee B; Fritsch WP; Hausamen TU; Grosse-Brockhoff F
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1662-4. PubMed ID: 611905
    [No Abstract]   [Full Text] [Related]  

  • 11. Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution.
    Keller F; Molzahn M; Ingerowski R
    Eur J Clin Pharmacol; 1980 Nov; 18(5):433-41. PubMed ID: 7439268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Letter: Kinetics of elimination and dosage of digoxin in patients with kidney failure].
    Risler T
    Dtsch Med Wochenschr; 1974 Oct; 99(42):2130-1. PubMed ID: 4426236
    [No Abstract]   [Full Text] [Related]  

  • 14. Digoxin pharmacokinetics and dosage requirements in pediatric patients.
    Bendayan R; McKenzie MW
    Clin Pharm; 1983; 2(3):224-35. PubMed ID: 6349908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. I. Off dialysis.
    van der Vijgh WJ
    Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):249-54. PubMed ID: 881276
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of activated charcoal on digoxin and digitoxin clearance.
    Park GD; Goldberg MJ; Spector R; Johnson GF; Feldman RD; Quee CK; Roberts P
    Drug Intell Clin Pharm; 1985 Dec; 19(12):937-41. PubMed ID: 4085353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digoxin in the elderly and in renal failure. Contribution of erythrocyte 86-rubidium uptake tests.
    Zannad F; Royer RJ; Issartel G; Robert J
    Eur J Cardiol; 1981; 12(5):285-96. PubMed ID: 6265220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic studies of nifedipine and digoxin co-administration.
    Koren G; Zylber-Katz E; Granit L; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):39-42. PubMed ID: 3957488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute bioavailability of digoxin in chronic renal failure.
    Ohnhaus EE; Vozeh S; Nüesch E
    Clin Nephrol; 1979 Jun; 11(6):302-6. PubMed ID: 477047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.